同步放化疗在肺肿瘤中地位显著,但其神经毒性突出,发生率高达82%~96%,限制了临床应用和疗效提高[1]。氨磷汀(amifostin,又称阿米福汀)是美国FDA批准上市的第一个泛细胞保护剂(pen cytoprotective agent),又称WR.2721,最初是作为放射保护剂,是一种亲核性含硫的前体药物,在组织中 Synchrotron chemoradiation in lung cancer in a significant position, but its neurotoxicity, the incidence as high as 82% to 96%, limiting the clinical application and efficacy [1]. Amifostin (amifostin) is the first pen cytoprotective agent approved by the US FDA and is also known as WR.2721. It was initially used as a radioprotective agent and is a nucleophile Sulfur-containing prodrugs in tissues